The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer, has awarded the fifth cycle of its Research Fellowship Program, in which it will support seven projects for a total of $365,000 in its largest funding cycle to date.
Since 2015, the Foundation has awarded over $1.9 million in funding for innovative, high-quality research. In accordance with the Foundation’s Research Philosophy, CCF supports promising projects that are less likely to receive traditional funding. Open-access research that catalyzes collaboration and focuses on finding a cure is a core value of the program.
2019 Fellowship Recipients
Theodorous Michelakos, MD, Massachusetts General Hospital (MGH)—B7-H3 specific CAR T-cell combinatorial immunotherapy for intrahepatic cholangiocarcinoma.
Jacquelyn Russell, PhD, Boston Children’s Hospital—Investigating YAP inhibition as a novel treatment for intrahepatic cholangiocarcinoma.
Saireudee Chaturantabut, PhD, Broad Institute of MIT & Harvard—Targeting FGFR2 signaling in gholangiocarcinoma.
Emilien Loueuillard, PhD, Mayo Clinic—Immunosuppressive myeloid cells facilitate tumor progression in cholangiocarcinoma.
Edward Jarman, PhD, University of Edinburgh—Understanding DKK1/GRP78 interactions and the implications for the tumor microenvironment in cholangiocarcinoma.
Meng-Ju Wu, PhD, MGH—Deciphering the role of the IDH mutant in the tumor immune microenvironment of cholangiocarcinoma.
Qianfei Zhang, MD, NCI/NIH—Gut microbiome-dependent accumulation of myeloid cells promotes intrahepatic cholangiocarcinoma. ■
